PGP and breast cancer: Thus, a non-competitive inhibitor, zosuquidar (20 μM), a conformational monoclonal antibody, UIC2, and a P-gp substrate used in chemotherapy treatment of breast cancer, doxorubicin (20 μM), have been used.